Adempas is the first and only medicine approved to treat adults with chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) that was treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or that cannot be treated with surgery (inoperable). The Adempas clinical studies included mostly patients with WHO functional class II-III symptoms. It is not known if Adempas is safe and effective in children.
WHO=World Health Organization
How far might Adempas take you?
Adempas can help increase the ability to walk farther (measured by a 6-minute walk distance [6MWD] test), and improve some CTEPH symptoms. A 6MWD test determines how far patients can walk in 6 minutes. Doctors may use it periodically to measure any changes in progress.
A 16-week study of 261 adults with CTEPH (WHO Group 4) showed that patients who took Adempas walked farther during the 6MWD test compared to patients who did not take Adempas.
CHANGE IN 6MWD AT THE END OF 16 WEEKS
A 16-week study of 261 adults with CTEPH (WHO Group 4) showed that patients who took Adempas walked farther during the 6MWD test compared to patients who did not take Adempas.
50%as many patients who took Adempas improved their WHO functional class compared to patients who took a placebo (no Adempas).
33% of Adempas patients showed WHO functional class improvement vs 15% of placebo patients.
Q+A: Patient Perspective
Below, watch one patient share her CTEPH diagnosis story.
DIAGNOSING MY CTEPH
Considering Adempas?
Learn more about support for our patients here.